19:01 , May 8, 2017 |  BC Innovations  |  Distillery Techniques

Disease models

TECHNOLOGY: Transgenics and knockouts Mice expressing a BSG mutation could be useful for screening therapies to treat early-onset high myopia. Whole-exome sequencing in 18 patients and their 36 unaffected parents identified 20 de novo heterozygous mutations...
01:47 , Feb 2, 2017 |  BC Innovations  |  Distillery Therapeutics

Infectious disease

INDICATION: Malaria In vitro and cell culture studies identified a thermally stable P. falciparum Rh5 variant that could be used in malaria vaccines. The variant consisted of a C-terminal fragment of wild-type P. falciparum Rh5 engineered...
23:38 , Nov 21, 2016 |  BioCentury  |  Strategy

LG’s biotech legacy

LG Life Sciences Ltd. was a pioneer, producing the first globally approved drugs developed by a South Korean company. A shift in priorities all but stopped the flow of innovative new drugs to the world...
07:00 , Sep 10, 2015 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Basigin Ok blood group (BSG; EMMPRIN; CD147); P. falciparum reticulocyte-binding protein homolog 5 (PfRh5)

Infectious disease INDICATION: Malaria Cell culture and mouse studies suggest inhibiting BSG could help treat malaria. A screen of mAbs from mice immunized with BSG ectodomains identified a mAb that decreased binding between BSG and the Plasmodium...
07:00 , Jun 26, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Bacterial infection; meningitis Basigin Ok blood group (BSG; EMMPRIN; CD147); Neisseria meningitidis type IV pilus assembly protein...
07:00 , Jun 26, 2014 |  BC Innovations  |  Targets & Mechanisms

Managing meningitis

SHX Vaccines is taking a new approach to vaccinating against meningitis-preventing meningococci from binding to host cells in the first place. The company's university collaborators have shown proof of concept for the approach in human...
08:00 , Dec 1, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Infectious disease

Indication Target/marker/pathway Summary Licensing status Publication and contact information Infectious disease Malaria Plasmodium falciparum reticulocyte-binding protein homolog 5 (PfRh5); basigin Ok blood group (BSG; EMMPRIN; CD147) In...
08:00 , Dec 1, 2011 |  BC Innovations  |  Cover Story

Turning back the malarial hordes

Researchers from the Wellcome Trust Sanger Institute have identified a host receptor, basigin Ok blood group, that allows Plasmodium falciparum to invade erythrocytes and trigger a blood-stage malaria infection.1 The researchers are now developing a...
08:00 , Feb 17, 2011 |  BC Innovations  |  Targets & Mechanisms

EMMPRIN's new clothes

EMMPRIN dropped off the drug discovery map in 2003 when Abgenix Inc.'s antibody against the target failed in a Phase II/III trial to treat graft-versus-host disease. Now, findings from Canadian researchers suggest it might be...
08:00 , Feb 3, 2011 |  BC Innovations  |  Distillery Therapeutics

Indication: Autoimmune disease

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Autoimmune disease Multiple sclerosis (MS) Basigin Ok blood group (BSG; EMMPRIN; CD147) Patient...